Revistas
Revista:
CANCERS
ISSN:
2072-6694
Año:
2023
Vol.:
15
N°:
11
Págs.:
3056
Simple Summary: This study evaluates the occurrence of second primary neoplasms (SPNs) in individuals with a history of melanoma (MM) and identify factors that increase the risk in our population. A prospective cohort study was conducted, involving 529 MM survivors from January 2005 to August 2021. Among the 529 patients, 89 were diagnosed with SPNs, with 62 being skin tumors and 37 being solid organ tumors. The estimated probability of developing SPNs after MM diagnosis was found to increase over time, reaching 4.1% at 1 year, 11% at 5 years, and 19% at 10 years. Several factors were significantly associated with a higher risk of SPNs, including older age, primary MM location on the face or neck, and the histologic subtype of lentigo maligna MM. We conclude that individuals with primary MM located on the face and neck, as well as those with the histological subtype of lentigo maligna-MM, have a higher risk of developing SPNs. Age also independently influences the risk. Understanding these risk factors can assist in developing MM guidelines that provide specific follow-up recommendations for individuals at the highest risk. (1) Introduction: The association between melanoma (MM) and the occurrence of second primary neoplasms (SPNs) has been extensively studied, with reported incidence rates ranging from 1.5% to 20%. This study aims to evaluate the occurrence of SPNs in patients with a history of primary MM and to describe the factors that make the risk higher in our population. (2) Material and Methods: We conducted a prospective cohort study and calculated the incidence rates and relative risks (RR) for the development of different SPNs in 529 MM survivors from 1 January 2005 to 1 August 2021. Survival and mortality rates were obtained, and the Cox proportional hazards model was used to determine the demographic and MM-related factors that influence the overall risk. (3) Results: Among the 529 patients included, 89 were diagnosed with SPNs (29 prior to MM diagnosis, 11 synchronous, and 49 after MM), resulting in 62 skin tumors and 37 solid organ tumors. The estimated probability of developing SPNs after MM diagnosis was 4.1% at 1 year, 11% at 5 years, and 19% at 10 years. Older age, primary MM location on the face or neck, and histologic subtype of lentigo maligna mm were significantly associated with a higher risk of SPNs. (4) Conclusions: In our population, the risk of developing SPNs was higher in patients with primary MM located on the face and neck and with the histological subtype of lentigo maligna-MM. Age also independently influences the risk. Understanding these hazard factors can aid in the development of MM guidelines with specific follow-up recommendations for individuals with the highest risk.
Revista:
DERMATOLOGIC THERAPY
ISSN:
1396-0296
Año:
2022
Vol.:
35
N°:
9
Págs.:
e15709
The appearance of morphea after vaccination has been reported to date as single and deep lesions that appear exactly at the site of the skin puncture. It was therefore postulated that the origin could be the trauma related to the injection. The aim of this article is to review the various hypotheses offered in the published literature about generalized morphea following vaccination. We present two cases of generalized morphea after COVID-19 vaccination and review the published literature on immune-related cutaneous reactions. As previously reported, antigenic cross-reactivity between vaccine spike proteins and human tissues could cause certain immune-mediated diseases, including generalized morphea. Herein we report two cases of generalized morphea probably induced by the COVID-19 vaccine, given the temporal relationship with its administration. In summary, environmental factors such as vaccination against SARS-COV-2 could induce an immune system dysregulation, which would have an important role in the pathogenesis of morphea. We present two cases of generalized morphea probably induced by the COVID-19 vaccine, given the time elapsed between vaccination and the onset of the skin lesions.
Revista:
JOURNAL OF DERMATOLOGY
ISSN:
0385-2407
Año:
2021
Vol.:
48
N°:
3
Págs.:
380 - 384
Colony-stimulating factor 1 receptor (CSF1R) inhibitors represent a new class of immune-modulatory drugs, mostly investigated in clinical trials in different malignant neoplasms. Four patients, diagnosed with recurrent or advanced malignant neoplasm and treated with a combination of anti-programmed death ligand 1 and anti-CSF1R monoclonal antibodies, developed an asymptomatic cutaneous eruption characterized by an ill-defined pseudoedematous to waxy diffuse infiltration with a reticular cobblestone-like pattern. Histopathological examination revealed diffuse mucin deposition involving the superficial and mid-dermis with fragmented and scattered elastic fibers. The exact pathogenic mechanisms implicated in the development of mucin deposits in patients treated with CSF1R inhibitors remain to be elucidated. A reduced degradation and clearance of components of the extracellular matrix by macrophages secondary to CSF1 pathway inhibition may be hypothesized. Shredding and fragmentation of elastic fibers may be a result of the increased accumulation of mucopolysaccharides. This observation illustrates the new spectrum of skin-related toxicities secondary to new targeting therapies. This may contribute to a better understanding of the underlying pathogenic mechanisms in skin diseases characterized by a persistent dermal glycosaminoglycan deposition.
Revista:
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
ISSN:
1610-0379
Año:
2021
Vol.:
19
N°:
4
Págs.:
603 - 604
Revista:
EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. JOURNAL
ISSN:
1468-3083
Año:
2020
Vol.:
34
N°:
7
Págs.:
1464 - 1470
Background: Organ transplant recipients (OTR) have a higher risk of actinic keratosis (AK) and keratinocyte carcinomas (KC). There are no clinical trials assessing the effectiveness of daylight photodynamic therapy (DPDT) to prevent new AK and KC in OTR.
Objectives: To determine whether repeated treatments of field cancerization with DPDT are effective in preventing new AK and KC in OTR.
Methods: A randomized, intra-subject controlled, evaluator-blind, split-face and/or scalp trial, from April 2016 to October 2018. Participants were OTR older than 18 years, 1-year posttransplant, with at least 5 AK on each hemi-face/hemi-scalp. One side received six field treatments with DPDT: two sessions 15 days apart at baseline, two at 3 months and two at 9 months after baseline. Control side received lesion-directed treatment with cryotherapy (double freeze-thaw) at baseline, 3 and 9 months. Total number of lesions (AK and KC) at 21 months, number of new AK and KC at 3, 9, 15 and 21 months and treatment preferences were analysed.
Results: Of 24 men included, 23 were analysed at 3 months; and 21, at 9, 15 and 21 months. Mean (SD) age was 69.8 years (9.2). The total number of lesions at 21 months was 4.7 (4.3) for DPDT and 5.8 (5.0) for control side; P = 0.09. DPDT showed significantly lower means [SD] of new lesions compared to control side at 3 months (4.2 [3.4] vs. 6.8 [4.8]; P < 0.001), 9 months (3.0 [3.3] vs. 4.3 [3.4]; P = 0.04) and 15 months (3.0 [4.6] vs. 4.8 [5.0]; P = 0.02), and non-significant at 21 months (3.7 [3.5] vs. 5.0 [4.5]; P = 0.06). Most participants preferred DPDT.
Conclusion: DPDT showed potential effectiveness in preventing new AK and KC in OTR by consecutive treatments of field cancerization. The preference for DPDT could facilitate adherence to the long-term treatment necessary in these patients.
Revista:
MEDICINA CLINICA
ISSN:
0025-7753
Año:
2020
Vol.:
154
N°:
5
Págs.:
198
Revista:
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
ISSN:
1610-0379
Año:
2020
Vol.:
18
N°:
9
Págs.:
1028 - 1030
Revista:
ATENCION PRIMARIA
ISSN:
0212-6567
Año:
2019
Vol.:
51
N°:
10
Págs.:
654 - 655
Revista:
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
ISSN:
0190-9622
Año:
2015
Vol.:
72
N°:
Supl. 1
Págs.:
S73 - S75
Revista:
JAMA DERMATOLOGY
ISSN:
2168-6068
Año:
2015
Vol.:
151
N°:
8
Págs.:
897 - 899
Revista:
JOURNAL OF COSMETIC AND LASER THERAPY
ISSN:
1476-4172
Año:
2015
Vol.:
17
N°:
6
Págs.:
304-06
Epidermal nevi are benign proliferations of the epidermis for which different treatments have been used with disappointing results due to their recurrences and anesthetic scars. Topical therapies have generally been ineffective and surgical treatment provides more definitive results, but with high risk of scarring. In recent years, multiple laser modalities have been described for the treatment of these lesions. In the literature, there are no reported cases of treatment of these lesions with Neodymium-doped Yttrium aluminum garnet (Nd:YAG) laser. We present the case of a 3-year-old patient with a hemicorporal epidermal nevus treated with Nd:YAG laser at an early stage with good results.
Revista:
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
ISSN:
0190-9622
Año:
2015
Vol.:
73
N°:
2
Págs.:
e73 - e74
Revista:
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
ISSN:
0190-9622
Año:
2015
Vol.:
72
N°:
1
Págs.:
151 - 158.e1
Background Sturge-Weber syndrome (SWS) is characterized by port-wine stains (PWS) affecting the face, eyes, and central nervous system. Pulsed dye laser (PDL) is the standard treatment for PWS. Unfortunately, recurrence is frequent because of reformation and reperfusion of blood vessels. Objective We sought to assess the clinical efficacy of topical rapamycin combined with PDL in PWS of patients with SWS.
Methods We conducted a phase II, randomized, double-blind, intraindividual placebo-controlled, clinical trial. We recruited 23 patients with SWS and facial PWS (12 women; median age 33 years, age range 17-65 years) from the University Clinic of Navarra, Spain. Four interventions were evaluated: placebo, PDL + placebo, rapamycin, and PDL + rapamycin. Clinical and histologic responses were evaluated using a chromatographic computerized system, spectrometry, and histologic analyses at 6, 12, and 18 weeks after the intervention.
Results PDL + rapamycin yielded the lowest digital photographic image score and the lowest percentage of vessels in histologic analysis, and showed a statistically significant improvement compared with the other interventions. The treatment was generally well tolerated.
Limitations PDL was only applied to the lateral parts of the PWS area. Conclusion Topical rapamycin associated with PDL seems to be an effective treatment for PWS in patients with SWS.
Revista:
JOURNAL OF COSMETIC AND LASER THERAPY
ISSN:
1476-4172
Año:
2014
Vol.:
16
N°:
6
Págs.:
314-6
Voriconazole is an antifungal agent mainly used against aspergillosis. Given its wide spectrum of action and limited adverse effects, it has replaced amphotericin B as the drug of choice in the prophylactic treatment of immunocompromised patients. Several adverse effects are caused by this drug with dermatological reactions accounting for 6% of the total. Such reactions include cheilitis, erythema, erosions, discoid lupus erythematosus, erythema multiforme, photosensitivity reactions, pseudoporphyria, accelerated photoaging and skin cancer. There are few reports on the accelerated photoaging caused by voriconazole and its effective treatment. Here we present the case of a 6-year-old child with a history of chronic granulomatous disease under prolonged treatment with voriconazole, who developed accelerated photoaging lesions secondary to the chronic use of this antifungal agent. Treatment was initiated using Q-switched Nd:YAG laser with good results.
Revista:
JAMA DERMATOLOGY
ISSN:
2168-6068
Año:
2014
Vol.:
150
N°:
6
Págs.:
664 - 666
Revista:
MEDICINE (ELSEVIER)
ISSN:
0304-5412
Año:
2014
Vol.:
11
N°:
48
Págs.:
2868-2863
Revista:
MEDICINE (ELSEVIER)
ISSN:
0304-5412
Año:
2014
Vol.:
11
N°:
48
Págs.:
2883e1 - 2883e5
Revista:
EXPERIMENTAL DERMATOLOGY
ISSN:
0906-6705
Año:
2013
Vol.:
22
N°:
12
Págs.:
838 - 839
Pachyonychia congenita is a rare, autosomal dominant genetic disease characterized by painful palmoplantar keratoderma and hypertrophic nail dystrophy. This disorder is caused by mutations in any one of five cytoskeletal keratin proteins, K6a, K6b, K6c, K16 and K17. Here, we describe a new p.Leu421Pro (c.1262T>C) mutation in the highly conserved helix termination motif of K16 in a large Spanish family. Bioinformatic analyses as well as previous descriptions in the literature of homologous mutations in other keratin-coding genes show that this mutation is probably causative of the disease.
Revista:
ACTAS DERMO-SIFILIOGRAFICAS
ISSN:
0001-7310
Año:
2013
Vol.:
104
N°:
8
Págs.:
724-5
Revista:
ACTAS DERMO-SIFILIOGRAFICAS
ISSN:
0001-7310
Año:
2013
Vol.:
104
N°:
7
Págs.:
617-622
Revista:
JOURNAL OF COSMETIC AND LASER THERAPY
ISSN:
1476-4172
Año:
2013
Vol.:
15
N°:
4
Págs.:
207-9
Partial unilateral lentiginosis (PUL) is a rare pigmentary disorder characterized by multiple lentigines grouped within an area of normal skin, often in a segmental pattern and appearing at birth or in childhood. There is no established standard treatment for this condition. We present two cases of PUL succesfully treated with alexandrite Q-switched laser. In our cases, this laser proved to be a safe and effective treatment for cosmetically disfiguring lentigines. Special precautions are needed when treating dark-skinned patients because side effects are more likely. We propose that this modality be considered in the treatment of this rare disorder.
Autores:
Basset-Seguin, N; Baumann Conzett, K; Gerritsen, MJ; et al.
Revista:
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
ISSN:
0926-9959
Año:
2013
Vol.:
27
N°:
1
Págs.:
57-66
This position article summarizes those discussions and makes recommendations concerning a standardized protocol for treating OTRs, for a large randomized controlled trial to provide robust data on safety, efficacy and optimal pain control, and to provide pharmaco-economics data that can be used to support extended reimbursement in this patient group. The authors also recommend a second clinical trial to further investigate induced immunosuppression with PDT in healthy volunteers.
Revista:
ANNALS OF PHARMACOTHERAPY
ISSN:
1060-0280
Año:
2013
Vol.:
47
N°:
3
Págs.:
e16
This appears to be the first report of a case of TEN that occurred in a patient being treated with oral tranexamic acid. Clinicians should be made aware of this potential severe cutaneous adverse reaction that may be caused by tranexamic acid administration.
Revista:
Journal of the American Academy of Dermatology
ISSN:
0190-9622
Año:
2011
Vol.:
65
N°:
5
Págs.:
893 - 906
There is significant confusion in the literature when describing vascular anomalies, and vascular malformations are often misnamed or incorrectly classified. Part I of this two-part series on the diagnosis and management of extensive vascular malformation
Revista:
Journal of the American Academy of Dermatology
ISSN:
0190-9622
Año:
2011
Vol.:
65
N°:
5
Págs.:
909 - 923
At least nine types of vascular malformations with specific clinical and radiologic characteristics must be distinguished in the lower limbs: Klippel¿Trénaunay syndrome, port-wine stain with or without hypertrophy, cutis marmorata telangiectatica congenit
Revista:
PIEL
ISSN:
0213-9251
Año:
2011
Vol.:
26
N°:
6
Págs.:
285-90
Revista:
British Journal of Dermatology (Print)
ISSN:
0007-0963
Año:
2010
Vol.:
162
N°:
2
Págs.:
350 - 356
Revista:
ARCHIVES OF DERMATOLOGY
ISSN:
0003-987X
Año:
2010
Vol.:
146
N°:
12
Págs.:
1347 - 1352
:
The presence of pulmonary arterial hypertension in patients with extensive slow-flow vascular malformations is not an isolated feature but is relatively frequent. Levels of D-dimer correlate with PASP in these patients.
Revista:
BRITISH JOURNAL OF DERMATOLOGY
ISSN:
0007-0963
Año:
2010
Vol.:
162
Págs.:
1156
Nacionales y Regionales
Título:
Desarrollo de formulaciones innovadoras con nanopartículas mucoadhesivas para el tratamiento de úlceras mucosales (NANOMUC)
Código de expediente:
RTC-2015-4437-1
Investigador principal:
Ana Gloria Gil Royo
Financiador:
MINISTERIO DE CIENCIA E INNOVACIÓN
Convocatoria:
2015 MINECORETOS-COLABORACION
Fecha de inicio:
24/02/2015
Fecha fin:
30/06/2018
Importe concedido:
159.264,00€
Otros fondos:
-
Título:
Estudio prospectivo aleatorizado y controlado de eficacia a largo plazo del láser CO2 en pacientes con enfermedad de Hailey-Hailey. Valoración del cambio de expresión génica.
Código de expediente:
PID2020-114340RA-I00
Investigador principal:
Leyre Aguado Gil
Financiador:
AGENCIA ESTATAL DE INVESTIGACION
Convocatoria:
2020 AEI PROYECTOS I+D+i (incluye Generación del conocimiento y Retos investigación)
Fecha de inicio:
01/09/2021
Fecha fin:
31/08/2024
Importe concedido:
84.700,00€
Otros fondos:
-